Objectives-To provide preliminary evidence that the currently employed semiquantitative method of screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can only detect infants who are totally deficient for G6PD and misses all cases of partial G6PD deficiency. Setting-General population: 2150 randomly selected blood samples from the Blood Donation Department, Speliopouleion General Hospital, Athens, Greece. Neonate population: 2000 samples from neonates (50% male; 50% female) in maternity hospitals in the greater Athens area. High risk population: a total of 545 individuals from 133 families in the Athens area, the minimum acceptance criteria being the parents and any brother or sister. Method-Blood specimens from neonates or adults were collected and either spotted and dried on special filter paper (Schleicher and Schull 2992, Darmstadt, Germany) or used in tubes after being heparinised. For the quantitative evaluation of G6PD enzyme activity, the Quantase G6PD screening kit (Quantase Limited, Perth, UK) was used. Quantase G6PD controls (Quantase Limited) were used at three levels of G6PD. These controls are rated at 24, 30, and 37°C. Alternatively, we used the Sigma G6PDH controls (Sigma Chemical Company, St Louis, USA) which are rated at 30 and 37°C. The assay was performed according to the instructions included in the kit with the modification for haemoglobin normalisation. Results-General population: 36 females who were classified as having normal enzymatic activity with the semiquantitative test, were classified as partially deficient with the quantitative test. Neonate population: using the quantitative test, the percentage of G6PD deficient neonates in this population was 5.5%, compared with 3.17% reported in routine screening using the semiquantitative method. High risk population: the quantitative method detected 28 cases of total or partial G6PD deficiency in sisters of males with known total deficiency. The semiquantitative method only detected 32% (nine out of 28) of these cases.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common genetic diseases aVecting an estimated 400 000 000 people worldwide. In Greece, where this disease is endemic, an estimated 225 000 males and 92 000 females are aVected. 1 Haematological problems arising in the G6PD deficient populations through exposure to oxidising xenobiotics have been well characterised, ranging from haemolysis of red blood cells and hereditary non-spherocytic haemolytic anaemia, to sepsis and life threatening kernicterus in the newborn. 2 3 6 Neonatal screening for G6PD is established in many countries, and the screening method most commonly used is the semiquantitative method described by Beutler, 4 or modifications to this method. 5 This method was believed to discriminate between deficient (partial or total deficiency) and normal cases. We provide preliminary evidence that this is not true because of the very low cut oV point this method employs (2.1 U/g haemoglobin (Hb)), which can only discover the totally deficient cases (<20% residual enzymatic activity), incorrectly classifying partially deficient neonates (residual enzymatic activity between 20 and 60%) as normal.
Neonatal screening for G6PD deficiency is long established. 1 8 From 1977 to 1998, 2 070 557 neonates have been screened for this deficiency at the Institute of Child Health, Athens, Greece. 1 The overall frequency of G6PD for Greek neonates was found to be 4.5% for males and 1.84% for females. These percentages are confirmed annually by the screening centre. The overall frequency of G6PD deficiency for the Greek population is calculated to be 3.17%. 1 It is evident that G6PD deficiency seems to aVect more boys than girls-a finding which has led to the characterisation of this disorder as being "male". Table 1 shows the genetic combinations that lead to either partial or total G6PD deficient individuals. This disorder, though X chromosome linked, is not recessive, 6 9 and both chromosomes are expressed resulting in two cell populations, which could be characterised as normal (G6PD + ) and deficient (G6PD − ). 9 10 These populations exist in a dynamic equilibrium, and the overall G6PD activity of the patient may vary greatly (20 to 60% of the normal residual activity). This is relevant for heterozygous females, since both chromosomes may become active at one time or another. Therefore, the heterozygous female's overall residual G6PD activity can be between 10 and 60% of normal enzymatic activity. This is characterised as "partial deficiency", and may lead to severe haemolytic attacks. 10 The combinations that lead to females homozygous for the mutated X (X mut ) chromosome (X mut X mut , total deficiency), or heterozygous (X mut X, partial deficiency) for G6PD suggest that there are more G6PD deficient (partial and total combined) females than males. In this table, each genetic combination is examined on its own, and the result is expressed as a percentage for each sex. Thus, in the first combination, in which both the mother and the father have normal X chromosomes, the percentage of males (or females) with normal activity is 100. In the second combination, in which the mother has one mutated chromosome, 50% of males are totally G6PD deficient, and 50% are not deficient. Females derived from the second combination are 50% partially deficient and 50% normal. The percentages (scores) that lead to either total or partial deficiency are then added and shown as the total ratios for the two sexes. OVspring from all possible genetic combinations exhibiting total deficiency will be a 2:1 ratio, male to female. This is almost identical to the ratio obtained from over 2 000 000 neonates screened in Greece. 1 Since males are always phenotypically deficient they test positive in screening. Hence the frequency of 4.5% males with total G6PD deficiency is not disputed here, and is used as a basis for theoretical calculations. If we apply the ratios calculated in table 1 (male to female = 2:1) to the percentage of deficient males (4.5%), we conclude that the totally deficient (homozygous) females should, theoretically, be 2.25%. This is very close to the observed frequency of 1.84% in Greece. Calculating the total number of aVected females (heterozygous plus homozygous) the figure should be 6.8%. If this is true, it would mean that 3.7 partially G6PD deficient females are undetected for each female with total G6PD deficiency who is detected. In Greece alone, this would bring the overall population of undiagnosed females during the last 20 years to >49 500.
Worldwide, the most commonly used procedure is the collection of Gurthie cards with dried blood spots from the neonates, which are then tested using a modification of the classic semiquantitative Beutler method. 1 5 This method has some major disadvantages. Namely, it is time consuming, temperature limited, and produces inadequate clinical information. 7 The most important drawback of this method is its low cut oV limit (<2.1 U/ g Hb) . It was believed that this cut oV was high enough to discover even partially deficient females. 1 The aim of this study was to provide preliminary evidence that this is not so. In fact, the semiquantitative method currently employed only finds total G6PD deficiency cases and misses all partially deficient ones. Additionally, we provide preliminary evidence that most (if not all) partially deficient female neonates are regularly classified as normal.
Setting

GENERAL POPULATION
In order to verify the diVerence between the quantitative and semiquantitative methods, we randomly selected 2150 blood samples from a blood donation department (Speliopouleion General Hospital of Athens, Athens, Greece) and we tested them for G6PD activity with both the semiquantitative method, which is employed by the screening centre (Institute of Child Health, Aghia Sophia Children Hospital, Athens, Greece), and the quantitative method (Quantase MMR500 kit, Quantase Limited, Perth, UK).
NEONATE POPULATION
Dried blood spots from 2400 neonates were submitted to our laboratory from 22 paediatricians working in maternity hospitals in the greater Athens area. Samples were collected on the same date by our staV and tested the day X mut = X chromosome bearing the G6PD deficiency. The ratio of deficient girls to boys is 600:400, or 3:2.
Figure 1: Formula expressing results in U/g Hb. −OD sample340nm /min is the kinetic result for the sample; −OD control340nm /min is the kinetic result for the control; Control Value is the value of the control designated for the temperature the test is run at, expressed in U/g Hb; OD sample405nm and OD control405nm are the extra readings at 405 nm, and are proportional to the Hb contents of the sample and the control respectively.
∆OD sample340nm /min/∆OD control340nm /min OD sample405nm /OD control405nm × Control Value = Sample Activity in U/g Hb after. Each paediatrician was asked to submit spots from 100 neonates in the raw (without omitting any neonate in between). The first 1000 males and first 1000 females to be delivered to our laboratory participated in this study.
HIGH RISK POPULATION
In order to support the theory that females who are partial G6PD deficient are missed, we requested the families of 378 infant boys diagnosed as G6PD deficient to participate in a quantitative G6PD analysis employing the Hb normalisation. A total of 237 families responded. We then selected the families who allowed us to perform the test on all family members (the minimum acceptance criteria being the parents and any brother or sister). A total of 133 families were then enrolled in the study-545 individuals.
Material and methods
Blood specimens from neonates or adults were collected according to the standard procedures previously described. 1 The blood was either spotted and dried on special filter paper (Schleicher and Schull 2992, Darmstadt, Germany), or used in tubes after being heparinised. Deficient males were identified during routine neonatal screening and their families were recalled for an additional G6PD evaluation. All donors had no diagnosed health problems at the time of blood sampling, and had not received any drugs during the last month prior to blood sampling. For the quantitative evaluation of G6PD enzyme activity, the Quantase MMR500 G6PD screening kit (Quantase Limited) was used. In a small number of samples we used the Quantase MMR010 G6PD single test kit (Quantase Limited), which uses the same assay protocol.
The kits utilise the chemical reaction described by Beutler, 4 5 and the NADPH produced is measured at 340 nm in kinetic mode (change of optical density per minute). The method involves an elution stage for the lysis of red blood cells and a photometric measurement of the kinetic reaction at 340 nm. The controls used were Quantase MMRC02 G6PD controls (Quantase Limited), which were supplied in three levels of G6PD activity (normal = 17 U/g Hb, intermediate = 3.5 U/ g Hb, and deficient = 0.5 U/g Hb). The controls were rated at 24, 30, and 37°C. Alternatively, we used Sigma G6PDH controls (Sigma Chemical Company, St Louis, USA) product G6888 (normal; nominal value 10 U/ g Hb at 30°C, 14 U/g Hb at 37°C), product G5029 (intermediate; nominal value 3.7 U/ g Hb at 30°C) and product G5888 (deficient; nominal value 0.6 U/g Hb at 30°C). The main diVerence in these controls is diVering temperature ratings (Sigma's controls are rated at 30 and 37°C only), and their shelf life following reconstitution (five days following reconstitution at 2 to 8°C for the Sigma compared to 30 days for the Quantase controls).
The assay was performed according to the instructions, with the modification for Hb normalisation as already described. 7 A paper disk with a 3/16 inch diameter, or 5 µl of whole blood was placed in each well of a round bottomed 96 well microplate. Then, 70 µl of elution buVer was added per well, and the microplate was agitated on an orbital shaker for 22 minutes. During the elution stage, the reagents were reconstituted and mixed. Upon completion of the elution stage, 15 µl of eluant was transferred to a new round bottomed microplate and 75 µl of the reagent mixture was added to each well. Two minutes after addition of the reagents, the plate was read in an ELISA microplate reader equipped with a 340 nm optical filter in kinetic mode. Twenty one measurements were taken at one minute intervals and the G6PD activity calculated as a change of optical density (OD) per minute (−OD/min). All experiments were performed at 37°C, except where otherwise stated. Following termination of the kinetic, the whole plate was read once at 405 nm to estimate Hb content, which is directly proportional to the number of lysed red cells.
The samples were normalised (against the control) for their Hb content (relative Hb values). All activities obtained were then divided by the relative Hb values giving the absolute activities (expressed in U/g Hb). 7 In all experimental setups, at least seven controls were run in order to verify our results. Thus, when Quantase controls were used, we included the same Quantase controls along with the Sigma controls as samples. The same procedure was followed when Sigma controls were used for comparison. One set of new controls was used for each reconstituted vial of Quantase MMR500 reagents, and a new control was used every day even if the same vial of reagents was used. 7 It should be noted that the quantitative kit used in this study was compared to both the standard method using RBC, 16 as well as other quantitative kits, and the results were almost identical (data not shown). On top of that, the use of the normalisation procedure allowed us to test dried blood spots and whole blood samples derived from the same individual simultaneously. As previously shown, 7 results from dried blood spots and whole blood were identical. Fig 1 shows the equation that was used to express our results directly in U/g Hb (Hb normalisation procedure). This formula is analytically described elsewhere. 7 This procedure allows the simultaneous testing of both dried blood spots and whole blood samples (or Red Blood Cell (RBC) washed in normal saline) in the same microplate, and was used for confirmation of our results.
EXPRESSING RESULTS IN UNITS/GRAM HB
DATA CONFIRMATION
An independent laboratory, using another quantitative kit and separate Hb evaluation subsequently tested all individuals participating in the "high risk population", for confirmation of our results.
Results
GENERAL POPULATION
Results from 2150 randomly selected blood samples tested for G6PD activity using both the semiquantitative method employed by the screening centre, and the quantitative method, are shown in table 2. Twenty four females were classified as having normal G6PD activity with the semiquantitative test, while the quantitative test classified them as partially deficient (intermediate; 10 to 60% of residual activity).
FREQUENCY DISTRIBUTION
The frequency distribution of the enzymatic activity of G6PD was calculated for a sample of 1000 males and 1000 females. The average G6PD activity of our sample population was measured at 10.6 U/g Hb (at 37°C). Therefore, we used 6.4 U/g Hb (60% of this value) as the upper limit of partial G6PD deficiency (intermediate activity) and 2.1 U/g Hb (20% of this value) as the upper limit for total G6PD deficiency as presented in table 3. There were 3.1% (62) neonates below the 2.1 U/g Hb mark who were classified as having total G6PD deficiency and 5.5% (110) neonates below 6.4 U/g Hb who were classified as G6PD deficient (partial plus total). Thus, the total percentage of G6PD deficient neonates was 5.5%, as compared to 3.17% found in routine screening. The theoretical value expected was 5.65%.
HIGH RISK POPULATION
Results from 545 individuals who were selected were screened for G6PD activity using both the semiquantitative method employed by the screening centre (Athens, Greece) and the quantitative method. In this population, the percentage of G6PD deficient individuals should be much higher than in the general population. Table 4 shows that only 32% (nine out of 28) of sisters with total or partial deficiency detected using the quantitative method were detected using the semiquantitative method. In the confirmation tests performed by an independent laboratory, all but two cases gave almost identical results. One of these cases was found to be partially deficient in a subsequent testing six months later. The other case showed a borderline value in her test (6.7 U/g Hb at the independent laboratory v 6.3 U/g Hb in our laboratory).
Discussion
Neonatal screening for G6PD deficiency is long established, and there have been many published results from mass screening around the world. In Greece, screening for G6PD has been established for 20 years, and the results show a higher frequency of aVected males than females, 1 a finding which correlates well with reports from other screening centres. [11] [12] [13] [14] G6PD, though X chromosome linked, is not recessive, 6 9 and both chromosomes are expressed resulting in two cell populations; normal (G6PD + ) and deficient (G6PD − ). 9 10 These populations exist in a dynamic equilibrium, and the overall G6PD activity of the patient may vary greatly (20 to 60% of the normal residual activity).
The actual G6PD content of the cell is not the only critical factor that determines the possibility for the development of a haemolytic episode. Other factors play an important role too, among them the aYnity of the existing G6PD for the substrate, or the generation of new red blood cells following the female's menstrual cycle. 9 Environmental factors such as specific infections, administration of contraindicated drugs or food, and contact with mothballs have been reported to induce haemolysis in G6PD deficient subjects. It has also been shown that the same neonate can have a higher or lower G6PD activity in subsequent measurements. 1 This could be attributed to the increased susceptibility of the G6PD populations to peroxide toxification, or other parameters. Therefore, the measurement of low G6PD activity should be interpreted as a warning factor, defining a high risk population, and special precautions should be taken.
It was recently shown, 15 that G6PD plays an embryoprotective role in developmental oxidative stress and chemical teratogenesis in mice. Consequently, litters from G6PD deficient animals showed an increased incidence of prenatal and postnatal death. It was further shown that developmental risk was potentially substantial even for heterozygous G6PD deficient animals. These findings support Grandmother/F or /M corresponds to the mother of the father or the mother respectively. Grandfather/F or /M corresponds to the father of the father or the mother respectively. The results shown in this table were obtained with a quantitative kit. Results shown in the "Previously detected" column were obtained with the semi-quantitative method.
our opinion that G6PD partially deficient individuals should be regarded as being equally at risk as totally G6PD deficient individuals.
The female heterozygote should be warned as early in life as possible and treated as if she was a totally G6PD deficient. Heterozygous females are at risk of developing haemolytic episodes, even severe ones, therefore detection of partial G6PD deficiency is of great importance. 10 A 16 year old female was recently hospitalised because of a severe haemolytic episode following consumption of fava beans. The girl was classified as normal during neonatal screening, but she was classified as partially deficient when the quantitative method was used (unpublished results). This case provides some evidence that the "partially G6PD deficient" females may face life threatening conditions if preventive measures are not taken. This particular female had an activity measured at 5.5 U/g Hb, which suggests that even individuals with relatively high enzymatic activity are still at potential risk as long as the activity is below the 6.4 U/g Hb mark.
It is generally accepted that if the residual G6PD activity in neonates is lower than 60% of normal enzymatic activity they should be classified as "G6PD deficient", and preventive measures should be taken. 10 Our results provide evidence that there are more "G6PD deficient" females than males. This finding contradicts the findings of screening centres, which classify more males than females as deficient. 1 11-14 Our preliminary results show that if the 2.1 U/g Hb mark is to be used as the cut oV point, then the results obtained with the quantitative and semiquantitative methods are almost identical. However, the average activity of our sample neonate population was found to be 10.6 U/g Hb, therefore the cut oV limit should be set to around 6.4 U/g Hb. Any neonate with an activity below this mark should be regarded as G6PD deficient, and all preventive measures should be taken.
When the 6.4 U/g Hb is used as the cut oV point, the number of female neonates who fall within this range of enzymatic activity levels (0 to 6.4 U/g Hb) is greater than the number of male neonates. Working with a small sample (n=2000) of Greek neonates, we showed that the male to female deficient neonate ratio should be 1:1.5 instead of 2.44:1. Moreover, the frequency of this disorder among Greek neonates should be >5.5% as compared to 3.17%. 1 It is clear that a large number of neonates are not diagnosed during screening, and these neonates are exclusively heterozygous females.
This hypothesis was investigated in a group of families which had (at least) one G6PD deficient male. Since deficient males were detected during screening, we chose families who had at least one deficient boy. Our results, using a G6PD quantitative kit, showed that the partially G6PD deficient females were not diagnosed with the semiquantitative kit. In this population we discovered 11 mothers who were totally G6PD deficient. Five of them were married to men with normal enzymatic activity and had a daughter. Though no daughter in these five families was diagnosed as G6PD deficient with the semiquantitative method, all of them were classified as deficient with the quantitative test. In fact the semiquantitative method only detected 32% of partially G6PD deficiency cases in sisters with an aVected brother detected by the quantitative method.
The total population sample used in this study is rather small (despite the high frequency of this disorder in Greece) for final conclusions to be drawn, and the actual frequency needs to be determined using a much larger population sample. It is evident that further work should be done with larger population samples to determine a cut oV point that can be used for the correct classification of neonates during screening. Our data suggest that the semiquantitative test usually employed in mass screening cannot detect female heterozygotes. Since female heterozygotes can also develop severe haemolytic episodes, it is of utmost importance to classify them correctly by screening during the neonatal period.
It is concluded that there is a vast population of undiagnosed partially G6PD deficient females. Therefore, screening centres must employ fully quantitative kits and recalculate the frequency of G6PD deficiency in their countries. The new screening kit has been tested and was found to be very reliable and accurate by various laboratories. 7 14 17 Since the semiquantitative test does not appear to miss any G6PD deficient male neonates, it is proposed that for financial reasons, quantitative screening could be limited to female neonates, especially in countries in which the prevalence of this deficiency is high.
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